Literature DB >> 14698081

The possibility of using mifepristone for menstrual induction.

Marc Bygdeman1.   

Abstract

Menstrual induction is a variant of suction aspiration that was originally defined to be performed in women with a menstrual delay of up to 2-3 weeks without knowing if the women is pregnant or not. Prerequisites for a pharmacological method for menstrual induction are a high efficacy to induce a bleeding in nonpregnant women and an expulsion of the pregnancy in pregnant women. Treatment with prostaglandins, specifically intramuscular sulprostone, can be as effective as suction aspiration for menstrual induction. However, the administration of prostaglandin in therapeutically effective doses was associated with a high frequency of gastrointestinal side effects and, to a lesser extent, of strong abdominal pain, which limited their routine use. More recent studies indicate that mifepristone in combination with either misoprostol or gemeprost is a more promising alternative. Further studies to identify the best treatment schedule are, however, needed, as is a randomized comparison with suction aspiration before a pharmaceutical method can be recommended.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14698081     DOI: 10.1016/s0010-7824(03)00148-3

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

1.  Effectiveness and Safety of Lower Doses of Mifepristone Combined With Misoprostol for the Termination of Ultra-Early Pregnancy: A Dose-Ranging Randomized Controlled Trial.

Authors:  Cui-Lan Li; Dun-Jin Chen; Li-Ping Song; Yan Wang; Zhong-Fang Zhang; Ming-Xing Liu; Wei-Ling Chen
Journal:  Reprod Sci       Date:  2014-11-12       Impact factor: 3.060

2.  Early medical abortion with self-administered low-dose mifepristone in combination with misoprostol.

Authors:  Li-Ping Song; Shi-Yan Tang; Cui-Lan Li; Lee-Jaden-Gil-Yu-Kang Zhou; Xue-Tang Mo
Journal:  J Obstet Gynaecol Res       Date:  2018-07-05       Impact factor: 1.730

Review 3.  Clinical Utility of Mifepristone: Apprising the Expanding Horizons.

Authors:  Zalak V Karena; Harsh Shah; Hetvee Vaghela; Kalp Chauhan; Pranav K Desai; Asjad Raza Chitalwala
Journal:  Cureus       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.